GlassScriptPhysician profile
Rallabhandi Sankaram
NPI 1710090766
$2,772.08
in general payments reported to CMS, 2019-2025
17 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $237 · 2021: $180 · 2022: $946 · 2023: $443 · 2024: $235 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,008.31 | 2019-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $296.96 | 2019-2025 | |
| Akebia Therapeutics INC | $215.63 | 2019-2021 | |
| Glaxosmithkline, LLC. | $161.12 | 2022-2023 | Jesduvroq |
| Amgen INC. | $153.25 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $139.24 | 2023-2024 | Farxiga |
| Nxstage Medical, INC. | $125.73 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $124.09 | 2019 | |
| Horizon Therapeutics Plc | $121.73 | 2022-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $85.08 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $60.59 | 2019 | |
| Travere Therapeutics, INC. | $59.99 | 2024 | |
| Aurinia Pharma U.S., INC. | $55.31 | 2021-2022 | |
| Janssen Research & Development, LLC | $52.00 | 2019 | |
| Opko Pharmaceuticals, LLC | $47.85 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $35.67 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rallabhandi Sankaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.